Co-arrangement between SciLifeLab Drug Discovery and Development platform and AstraZeneca
Biomarkers have influence on understanding of disease mechanism, optimize the chance for successful patients’ selection and outcomes of clinical trials and thus may contribute to minimizing cost of a drug development. In drug discovery, the accompanying discovery of potential biomarkers and the subsequent development as tools to identify patients that can benefit from treatment and to demonstrate a pharmacological response to the exploratory drug are therefore of increasing importance. In this minisymposium, we gather international academic and industrial experts to review state-of-the-art and new initiatives. Please, take the chance to discuss your own project with the speakers during the day.
Vendela Parrow, Pawel Baranczewski, Rebecka Klintenberg & Kristian Sandberg, SciLifeLab Drug Discovery and Development Platform; Anna Sandström, AstraZeneca
Kristian Sandberg, SciLifeLab/DDD and Anna Sandström, AstraZeneca
|10:15||Biomarkers in 21st Century Drug Development
Virginia Byers Kraus, MD, PhD (Durham, North Carolina, US)
|11:00||Transforming Drug Research and Development with Genomics’
Jan Fleckner, PhD, AstraZeneca VP, Diagnostic Expert
|11:30||Turning a biomarker candidate into a diagnostic for clinical use
Joachim Reischl, AstraZeneca VP, Head of Policy, Portfolio & Externalisation
|12:00||Lunch and mingle
|13:00||Rigging diagnostics for new predictive biomarkers – the Genomic Medicine Sweden initiative
Johan Botling, MD, PhD, Uppsala University
|13:30||Truly Translational – helping the small to think big. Biomarker strategies for SME’s
Karin von Wachenfeldt, PhD, CEO Truly Translational Sweden AB
|14:00||SCAN-B: transcriptome profiling of early breast cancer for identification of patients that may benefit from treatment
Åke Borg, PhD, Lund University
|14:30||Coffee and mingle
|15:00||Biomarkers in the development of KAND567 in acute myocardial infarction
Niclas Brynne, PhD, Chief Development officer at Kancera
|15:30||Panel discussion and concluding remarks
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.